JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

Search

AnaptysBio Inc

Slēgts

SektorsVeselības aprūpe

36.03 0.03

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

35.68

Max

38.31

Galvenie mērījumi

By Trading Economics

Ienākumi

699K

-39M

Pārdošana

-5.5M

22M

Peļņas marža

-173.517

Darbinieki

136

EBITDA

9.2M

-18M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+79.76% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 3. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

300M

1B

Iepriekšējā atvēršanas cena

36

Iepriekšējā slēgšanas cena

36.03

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

AnaptysBio Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 29. okt. 23:28 UTC

Karstas akcijas

Stocks to Watch: Chipotle, Align, Sprouts Farmers Market, Meta

2025. g. 29. okt. 23:07 UTC

Peļņas

Prudential PLC 3Q New Business Profit Up 13%

2025. g. 30. okt. 00:00 UTC

Peļņas

The Hamptons Luxury Housing Market Is Staging a Comeback for the Ages -- WSJ

2025. g. 30. okt. 00:00 UTC

Peļņas

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

2025. g. 30. okt. 00:00 UTC

Peļņas

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

2025. g. 29. okt. 23:46 UTC

Tirgus saruna

Nikkei May Decline Amid Caution Ahead of BOJ Decision -- Market Talk

2025. g. 29. okt. 23:40 UTC

Peļņas

Meta Shares Fall on Accelerating AI Spending Despite Record Revenue -- WSJ

2025. g. 29. okt. 23:38 UTC

Tirgus saruna

Gold Rises on Possible Dip-Buying After Falling on Powell's Remarks -- Market Talk

2025. g. 29. okt. 23:25 UTC

Peļņas

Alphabet Stock Jumps on Big Earnings Beat -- Barrons.com

2025. g. 29. okt. 22:51 UTC

Peļņas

Google Revenue Soars as AI Boom Lifts Cloud Business -- 2nd Update

2025. g. 29. okt. 22:45 UTC

Peļņas

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 6th Update

2025. g. 29. okt. 22:41 UTC

Peļņas

Prudential PLC 3Q New Business Profit Up 13% on Year to $705.0M >2378.HK

2025. g. 29. okt. 22:41 UTC

Peļņas

Prudential PLC APE Sales Up 10% on Year, to $1.72B >2378.HK

2025. g. 29. okt. 22:09 UTC

Peļņas

Microsoft Reports Strong Earning as Azure Cloud Revenue Soars by 40%. The Stock Is Still Down. -- Barrons.com

2025. g. 29. okt. 22:08 UTC

Tirgus saruna
Peļņas

Starbucks Revamps Stores in Pursuit of 'Warm' Atmosphere -- Market Talk

2025. g. 29. okt. 21:58 UTC

Peļņas

Alphabet Continues to Allocate More Resources to Waymo, CFO Says

2025. g. 29. okt. 21:58 UTC

Peļņas

Alphabet's Google Cloud Backlog Rose on Strong Demand for Enterprise AI, CFO Says

2025. g. 29. okt. 21:57 UTC

Peļņas

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 5th Update

2025. g. 29. okt. 21:54 UTC

Peļņas

Meta's Margins Are Slipping As AI Costs Mount. The Stock Is Falling. -- Barrons.com

2025. g. 29. okt. 21:46 UTC

Peļņas

Alphabet CEO Sees Strong Growth and Momentum for Waymo Continuing in 2026

2025. g. 29. okt. 21:43 UTC

Peļņas

Alphabet's Google Cloud Signing Larger Deals, Deepening Relationships With Existing Customers, CEO Says

2025. g. 29. okt. 21:43 UTC

Peļņas

Alphabet CEO: More Than 70% of Existing Google Cloud Customers Use AI Products

2025. g. 29. okt. 21:42 UTC

Peļņas

IGO 1Q Nova Cash Cost A$6.84/Pound, Up 72% On-Quarter

2025. g. 29. okt. 21:42 UTC

Peļņas

IGO 1Q Nova Copper Output 1,377 Tons, Down 41% On-Quarter

2025. g. 29. okt. 21:41 UTC

Peļņas

IGO 1Q Nova Nickel Sales 3,320 Tons, Down 5% On-Quarter

2025. g. 29. okt. 21:41 UTC

Peļņas

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 4th Update

2025. g. 29. okt. 21:41 UTC

Peļņas

Alphabet Signed New Google Cloud Customers Faster in 3Q, CEO Says

2025. g. 29. okt. 21:41 UTC

Peļņas

IGO 1Q Nova Nickel Production 3,429 Tons, Down 33% On-Quarter

2025. g. 29. okt. 21:40 UTC

Peļņas

IGO: Talks Ongoing With Kwinana JV Partner to Settle on Optimum Pathway For Refinery

2025. g. 29. okt. 21:39 UTC

Peļņas

IGO 1Q Kwinana Sustaining, Improvement Capex A$8.3 Million

Salīdzinājums

Cenas izmaiņa

AnaptysBio Inc Prognoze

Cenas mērķis

By TipRanks

79.76% augšup

Prognoze 12 mēnešiem

Vidējais 65 USD  79.76%

Augstākais 90 USD

Zemākais 20 USD

Pamatojoties uz 12 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi AnaptysBio Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

12 ratings

10

Pirkt

2

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

19.25 / 21.135Atbalsts un pretestība

Īstermiņā

Strong Bearish Evidence

Vidējā termiņā

Strong Bullish Evidence

Ilgtermiņā

Neutral Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
help-icon Live chat